The United States (US) has stepped up its support for eSwatini’s HIV response with the introduction of Lenacapavir, a long-acting antiretroviral that health experts believe could change the pace of treatment and prevention in the country.

The initiative is part of a wider effort involving the US government, pharmaceutical company Gilead Sciences and the Global Fund. Together, the partners aim to curb new HIV infections and bolster the resilience of health systems across Africa.

In an interview, US State Department Spokesperson Amanda Roberson said co-operation reflects how international partnerships can make a practical difference on the ground.

“Scientific advances only matter if they reach people,” Roberson noted. “What we’re doing in eSwatini is ensuring that communities have access to medicines that can genuinely lighten the burden of HIV. None of this is possible without strong collaboration with African health officials and local organisations.”

She said the programme is designed not only to expand access to modern HIV medicines but also to strengthen the systems that deliver care, including training, supply chains and community outreach.

eSwatini continues to carry one of the highest HIV prevalence rates in the world. Health workers in the country say long-acting options like Lenacapavir could be crucial in improving adherence and reducing the number of new infections in the years ahead.

–ChannelAfrica–